Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis

References

• Ardizzone S, Bianchi Porro G. (2002). Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med, 252, 475–496.
   PubMed Web of Science ®Google Scholar
• Crotty B, Jewell DP. (1992). Drug therapy of ulcerative colitis. Br J Clin Pharmacol, 34, 189–198.
   PubMed Web of Science ®Google Scholar
• Doh MJ, Jung YJ, Kim I, Kong HS, Kim YM. (2003). Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone. Arch Pharm Res, 26, 258–263.
   PubMed Web of Science ®Google Scholar
• Fagerholm U, Lindahl A, Lennernas H. (1997). Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol, 49, 687–690.
   PubMed Web of Science ®Google Scholar
• Friend DR, Chang GW. (1985). Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem, 28, 51–57.
   PubMed Web of Science ®Google Scholar
• Hugot JP, Zouali H, Lesage S, Thomas G. (1999). Etiology of the inflammatory bowel diseases. Int J Colorectal Dis, 14, 2–9.
   PubMed Web of Science ®Google Scholar
• Jung YJ, Doh MJ, Kim IH, Kong HS, Lee JS, Kim YM. (2003). Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone. J Pharm Pharmacol, 55, 1075–1082.
   PubMed Web of Science ®Google Scholar
• Kagan L, Hoffman A. (2008). Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv, 5, 681–692.
   PubMed Web of Science ®Google Scholar
• Kim IH, Kong HS, Choi BI, Kim YS, Kim HJ, Yang YW, Jung YJ, Kim YM. (2006). Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specific prodrug of dexamethasone. Drug Dev Ind Pharm, 32, 389–397.
   PubMed Web of Science ®Google Scholar
• Kim I, Kong H, Lee Y, Hong S, Han J, Jung S, Jung Y, Kim YM. 2009. Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine. Pharm Res, 26, 415–421.
   PubMed Web of Science ®Google Scholar
• Kong H, Kim Y, Lee Y, Choi B, Jung S, Jung Y, Kim YM. (2009). Sulfate-conjugated methylprednisolone: evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. J Drug Target, 17, 159–167.
   PubMed Web of Science ®Google Scholar
• McLeod AD, Tolentino L, Tozer TN. (1994). Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat. Biopharm Drug Dispos, 15, 151–161.
   PubMed Web of Science ®Google Scholar
• Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 795–803.
   PubMed Web of Science ®Google Scholar
• Nolen H III, Fedorak RN, Friend DR. (1995). Budesonide-beta-d-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci, 84, 677–681.
   PubMed Web of Science ®Google Scholar
• Robinson M. (1998). Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl, 90–98.
   PubMedGoogle Scholar
• Sack DM, Peppercorn MA. (1983). Drug therapy of inflammatory bowel disease. Pharmacotherapy, 3, 158–176.
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther, 96, 23–43.
   PubMed Web of Science ®Google Scholar
• Son MW, Ko JI, Doh HM, Kim WB, Park TS, Shim MJ, Kim BK. (1998). Protective effect of taurine on TNBS-induced inflammatory bowel disease in rats. Arch Pharm Res, 21, 531–536.
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature, 448, 427–434.
   PubMed Web of Science ®Google Scholar
• Yano H, Hirayama F, Arima H, Uekama K. (2001). Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J Pharm Sci, 90, 493–503.
   PubMed Web of Science ®Google Scholar
• Yano H, Hirayama F, Kamada M, Arima H, Uekama K. (2002). Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release, 79, 103–112.
   PubMed Web of Science ®Google Scholar
• Zhang X, Mehvar R. (2001). Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: plasma and tissue disposition. J Pharm Sci, 90, 2078–2087.
   PubMed Web of Science ®Google Scholar
• Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. (1999). Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos, 27, 479–485.
   PubMed Web of Science ®Google Scholar